PURPOSE: Patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite uncertainty in relapse risk. Here, we studied the ability of a recently developed model which combines clinicopathologic and gene expression variables (CP-GEP) to identify stage I/IIA melanoma patients who have a high risk for disease relapse. PATIENTS AND METHODS: Archival specimens from a cohort of 837 consecutive primary CMs were used for assessing the prognostic performance of CP-GEP. The CP-GEP model combines Breslow thickness and patient age, with the expression of eight genes in the primary tumour. Our specific patient group, represented by 580 stage I/IIA patients, was stratified based on their risk of relapse: CP-GEP High Risk and CP-GEP Low Risk. The main clinical end-point of this study was five-year relapse-free survival (RFS). RESULTS: Within the stage I/IIA melanoma group, CP-GEP identified a high-risk patient group (47% of total stage I/IIA patients) which had a considerably worse five-year RFS than the low-risk patient group; 74% (95% confidence interval [CI]: 67%-80%) versus 89% (95% CI: 84%-93%); hazard ratio [HR] = 2.98 (95% CI: 1.78-4.98); P < 0.0001. Of patients in the high-risk group, those who relapsed were most likely to do so within the first 3 years. CONCLUSION: The CP-GEP model can be used to identify stage I/IIA patients who have a high risk for disease relapse. These patients may benefit from adjuvant therapy.
PURPOSE:Patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite uncertainty in relapse risk. Here, we studied the ability of a recently developed model which combines clinicopathologic and gene expression variables (CP-GEP) to identify stage I/IIA melanomapatients who have a high risk for disease relapse. PATIENTS AND METHODS: Archival specimens from a cohort of 837 consecutive primary CMs were used for assessing the prognostic performance of CP-GEP. The CP-GEP model combines Breslow thickness and patient age, with the expression of eight genes in the primary tumour. Our specific patient group, represented by 580 stage I/IIA patients, was stratified based on their risk of relapse: CP-GEP High Risk and CP-GEP Low Risk. The main clinical end-point of this study was five-year relapse-free survival (RFS). RESULTS: Within the stage I/IIA melanoma group, CP-GEP identified a high-risk patient group (47% of total stage I/IIA patients) which had a considerably worse five-year RFS than the low-risk patient group; 74% (95% confidence interval [CI]: 67%-80%) versus 89% (95% CI: 84%-93%); hazard ratio [HR] = 2.98 (95% CI: 1.78-4.98); P < 0.0001. Of patients in the high-risk group, those who relapsed were most likely to do so within the first 3 years. CONCLUSION: The CP-GEP model can be used to identify stage I/IIA patients who have a high risk for disease relapse. These patients may benefit from adjuvant therapy.
Authors: Lodewyk F A Wessels; Marcel J T Reinders; Augustinus A M Hart; Cor J Veenman; Hongyue Dai; Yudong D He; Laura J van't Veer Journal: Bioinformatics Date: 2005-04-07 Impact factor: 6.937
Authors: Tina J Hieken; Travis E Grotz; Nneka I Comfere; Jonathan W Inselman; Elizabeth B Habermann Journal: Melanoma Res Date: 2015-04 Impact factor: 3.599
Authors: Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert Journal: N Engl J Med Date: 2018-04-15 Impact factor: 91.245
Authors: Jason J Luke; Paolo A Ascierto; Matteo S Carlino; Jeffrey E Gershenwald; Jean-Jacques Grob; Axel Hauschild; John M Kirkwood; Georgina V Long; Peter Mohr; Caroline Robert; Merrick Ross; Richard A Scolyer; Charles H Yoon; Andrew Poklepovic; Piotr Rutkowski; James R Anderson; Sama Ahsan; Nageatte Ibrahim; Alexander M M Eggermont Journal: Future Oncol Date: 2019-12-24 Impact factor: 3.404
Authors: Alyson L Mahar; Carolyn Compton; Susan Halabi; Kenneth R Hess; Jeffrey E Gershenwald; Richard A Scolyer; Patti A Groome Journal: Ann Surg Oncol Date: 2016-04-06 Impact factor: 5.344
Authors: Alexander Meves; Ekaterina Nikolova; Joel B Heim; Edwin J Squirewell; Mark A Cappel; Mark R Pittelkow; Clark C Otley; Nille Behrendt; Ditte M Saunte; Jorgen Lock-Andersen; Louis A Schenck; Amy L Weaver; Vera J Suman Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: Emily C Zabor; Daniel Coit; Jeffrey E Gershenwald; Kelly M McMasters; James S Michaelson; Arnold J Stromberg; Katherine S Panageas Journal: Ann Surg Oncol Date: 2018-02-22 Impact factor: 5.344
Authors: Edmund K Bartlett; Michael A Marchetti; Douglas Grossman; Susan M Swetter; Sancy A Leachman; Clara Curiel-Lewandrowski; Stephen W Dusza; Jeffrey E Gershenwald; John M Kirkwood; Amy L Tin; Andrew J Vickers Journal: Ann Surg Oncol Date: 2022-05-18 Impact factor: 4.339
Authors: Oliver J Wisco; Justin W Marson; Graham H Litchman; Nicholas Brownstone; Kyle R Covington; Brian J Martin; Ann P Quick; Jennifer J Siegel; Hillary G Caruso; Robert W Cook; Richard R Winkelmann; Darrell S Rigel Journal: Melanoma Res Date: 2022-04-01 Impact factor: 3.199
Authors: Aaron S Farberg; Justin W Marson; Alex Glazer; Graham H Litchman; Ryan Svoboda; Richard R Winkelmann; Nicholas Brownstone; Darrell S Rigel Journal: Dermatol Ther (Heidelb) Date: 2022-03-30
Authors: T Gambichler; L Susok; J Elfering; T Meyer; S Bruckmüller; E Stockfleth; M Skrygan; H U Käfferlein; T Brüning; K Lang; D Wagener; S Schröder; M Nick Journal: J Cancer Res Clin Oncol Date: 2021-11-10 Impact factor: 4.322